EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Malaria is caused by a germ that people get from the bites of some mosquitoes. It kills over
2 million people each year. Many of the drugs used to treat malaria do not work as well as
they used to and researchers are exploring other vaccines to prevent malaria. The purpose of
this study is to learn if the vaccine, called EBA-175 RII-NG, is safe and if it strengthens
the body's defenses against malaria. Participants will include 60 healthy adults, ages 18-40,
recruited from Accra, Ghana. Several dosages of the vaccine will be tested for safety. The
lowest dosages of the vaccine will be tested before the next higher dose is tested. There
will be two groups for each dose, one group will receive the vaccine and the other group will
receive a placebo (salt water solution). Participants may be involved in study related
procedures for up to 398 days.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)